Matt Gethers/20.380 HIV Project/Technical Paper/IP Outline: Difference between revisions
From OpenWetWare
Jump to navigationJump to search
No edit summary |
No edit summary |
||
Line 5: | Line 5: | ||
*After drug is approved we will begin treating first-world patients who can afford the initially expensive treatment | *After drug is approved we will begin treating first-world patients who can afford the initially expensive treatment | ||
*Simultaneously we will begin developing the same approach to treat other viral diseases such as the various hepatitis viruses | *Simultaneously we will begin developing the same approach to treat other viral diseases such as the various hepatitis viruses | ||
*We will seek patients’ | *We will seek patients’ and possibly non-infected blood donors to consent to us storing their engineered hematopoietic stem cells for future use in creating a library of stem cells | ||
**This will remove the necessity of drawing a patient's blood to generate patient-specific stem cells, lowering costs | |||
*Once we show our treatment is financially feasible, we will actively seek out funding from NGOs to expand our scope and begin treatment in third-world countries | *Once we show our treatment is financially feasible, we will actively seek out funding from NGOs to expand our scope and begin treatment in third-world countries | ||
*Our reservoir of HSCs and experience in treating first-world patients will reduce the cost of treating patients in the third-world enough to provide treatment to everyone | *Our reservoir of HSCs and experience in treating first-world patients will reduce the cost of treating patients in the third-world enough to provide treatment to everyone | ||
===Financial Considerations== | ===Financial Considerations=== | ||
*Figure out estimated costs to do this | *Figure out estimated costs to do this | ||
Revision as of 19:55, 15 April 2009
Timeline for Development & Conclusion
Company Timeline
- We will seek an initial round of funding to do initial in vitro and in vivo experiments
- After drug is approved we will begin treating first-world patients who can afford the initially expensive treatment
- Simultaneously we will begin developing the same approach to treat other viral diseases such as the various hepatitis viruses
- We will seek patients’ and possibly non-infected blood donors to consent to us storing their engineered hematopoietic stem cells for future use in creating a library of stem cells
- This will remove the necessity of drawing a patient's blood to generate patient-specific stem cells, lowering costs
- Once we show our treatment is financially feasible, we will actively seek out funding from NGOs to expand our scope and begin treatment in third-world countries
- Our reservoir of HSCs and experience in treating first-world patients will reduce the cost of treating patients in the third-world enough to provide treatment to everyone
Financial Considerations
- Figure out estimated costs to do this
Intellectual Property
- We will probably have to license the Glaser patent since it covers so much of our idea
- We will first attempt to purchase the exclusive rights to his patent for $XXX
- If that does not work, we will offer him a 25% (?) share of our equity and a position on our scientific advisory board
- The novel part of our idea is the use of stem cells to generate erythrocyte viral traps, and we will try to patent this aspect